Ligand to Report First Quarter 2026 Financial Results on May 7, 2026
Ligand (Nasdaq: LGND) will report first quarter 2026 financial results on Thursday, May 7, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Ligand (Nasdaq: LGND) will report first quarter 2026 financial results on Thursday, May 7, 2026. A conference call will begin at 8:30 a.m. Eastern to discuss results and provide a business update. Live webcast and replay will be available via the company’s webcast link.
Dial-in details include U.S. local, toll-free and international numbers with Meeting ID 304603090.
Details
News Market Reaction – LGND
On Apr 22, the day this news came out, LGND closed 0.09% above the previous close.
Data tracked by StockTitan Argus for the Apr 22 session.
Key Figures
- Earnings date
- May 7, 2026
- Scheduled first quarter 2026 financial results release
- Conference time
- 8:30 a.m. Eastern time
- Start time for Q1 2026 results conference call
- US local dial-in
- +1 (585) 542-9983
- United States local conference call number
- US toll-free dial-in
- +1 (833) 461-5787
- United States toll-free conference call number
- Meeting ID
- 304603090
- Conference call meeting ID for Q1 2026 results
Previous Earnings date Reports
-
Announced timing and access details for Q4 and full-year 2025 results call.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
JUPITER, Fla., April 22, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026. The company will hold a conference call beginning at 8:30 a.m. Eastern time to discuss the results and provide a general business update.
| Conference Call and Webcast Information | ||
| Date: | Thursday, May 7, 2026 | |
| Time: | 8:30 a.m. Eastern time | |
| Conference Call: | United States (Local): +1 (585) 542-9983 United States (Toll-Free): +1 (833) 461-5787 International: Global Dial-in Numbers Meeting ID: 304603090 | |
| Webcast: | Live and replay webcasts of the call are available here. | |
About Ligand
Ligand is a leading royalty aggregator, partnering with biopharmaceutical companies to finance and advance late-stage clinical development programs. Ligand owns and manages one of the largest and most diversified portfolios of biopharmaceutical royalties in the industry, with economic interests in more than 100 development and commercial-stage assets. Ligand funds high-value programs in exchange for long-term economic interests, aligning capital with clinical and commercial success. Ligand’s royalty portfolio is designed to deliver consistent and predictable revenue streams across a broad range of therapeutic assets. Ligand also licenses its proprietary technologies, Captisol® and NITRICIL™, to support drug development and formulation across its global partner network. For more information, visit www.ligand.com or follow Ligand on X and LinkedIn.
Contacts
Investors:
Melanie Herman
investors@ligand.com
(858) 550-7761
Media:
Kellie Walsh
media@ligand.com
(914) 315-6072
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.